Table 1 The clinicopathological characteristics of the CRC patients in the TCGA cohort used in this study.
From: WBSCR22 confers oxaliplatin resistance in human colorectal cancer
Characteristics | Cases (n = 348) | WBSCR22 mRNA expression | p | |
|---|---|---|---|---|
No. (%) | Low (n = 302) | High (n = 46) | ||
Gender | ||||
 Male | 191(54.9) | 164(54.3) | 27(58.7) | 0.577 |
 Female | 157(45.1) | 138(45.7) | 19(41.3) |  |
Age | ||||
 ≥60 | 227(65.2) | 196(64.9) | 31(67.4) | 0.741 |
 <60 | 121(34.8) | 106(35.1) | 15(32.6) |  |
Primary site | ||||
 Colon | 266(76.4) | 234(77.5) | 32(69.6) | 0.238 |
 Rectum | 82(23.6) | 68(22.5) | 14(30.4) |  |
Histological type | ||||
 Adenocarcinoma | 307(88.2) | 266(88.1) | 41(89.1) | 0.837 |
 Mucinous adenocarcinoma | 41(11.8) | 36(11.9) | 5(10.9) |  |
NMT stage | ||||
 Stage I + II | 187(53.7) | 164(54.3) | 23(50.0) | 0.585 |
 Stage III + IV | 161(46.3) | 138(45.7) | 23(50.0) |  |
Venous invasion | ||||
 Negative | 232(66.7) | 207(68.5) | 25(54.3) | 0.071 |
 Positive | 68(19.5) | 58(19.2) | 10(21.7) |  |
 Unkonw | 48(13.8) | 37(12.3) | 11(24.0) |  |
Lymphatic invasion | ||||
 Negative | 213(61.2) | 192(63.6) | 21(45.7) | 0.011 |
 Positive | 94(27.0) | 80(26.5) | 14(30.4) |  |
 Unkonw | 41(11.8) | 30(9.9) | 11(23.9) |  |
